Randomized trial demonstrates potent antiviral activity and favorable safety of ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C, indicating a viable interferon-free option.
In this difficult-to-treat population of patients in whom prior pegylated IFN/RBV had failed, ombitasvir/paritaprevir/ritonavir demonstrated potent antiviral activity with a favorable safety profile among Japanese patients with hepatitis C virus genotype 1b or 2a infection.
No takes yet. Share an insight, caveat, or question.
Chayama et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: